Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.44 |
| ▸ | JAK3 | P52333 | 4/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 13/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17153272 | 0.96 | TBK1 (0.44) | JAK2JAK3TBK1DYRK2CCNT1 | |
| SCHEMBL17152844 | 0.87 | PRKCA (0.44) | JAK2CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL17153233 | 0.86 | JAK2 (0.44) | JAK2JAK3TBK1ABL1PDGFRB | |
| SCHEMBL18412554 | 0.84 | PRKCA (0.42) | JAK2JAK3CCNT1CCNA2CDK2 | |
| SCHEMBL17153168 | 0.83 | PRKCA (0.43) | JAK2CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL17153142 | 0.81 | JAK2 (0.46) | JAK2JAK3TBK1CCNT1CCNA2 | |
| SCHEMBL17152843 | 0.80 | PRKCA (0.42) | CCNT1CCNA2CDK2CDK9ABL1 | |
| SCHEMBL17153109 | 0.79 | JAK2 (0.46) | JAK2JAK3TBK1CCNT1CCNA2 | |
| SCHEMBL17152976 | 0.79 | PRKCA (0.44) | JAK2JAK3CCNT1CCNA2CDK2 | |
| SCHEMBL17153228 | 0.79 | JAK2 (0.48) | JAK2JAK3TBK1ABL1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| US-20170022202-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150555-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022202-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | EEF2K, VPS26B, VPS28 | JAK2 2654/4885JAK3 3104/4885TBK1 296/4885 |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | EEF2K, VPS26B, VPS28 | JAK2 2654/4885JAK3 3104/4885TBK1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.